• CytoSorbents received a Nasdaq notice for failing the $35 million minimum market value of listed securities required for Nasdaq Capital Market listing.
• Nasdaq granted a 180-day cure period through Dec. 28, 2026 to regain compliance.
• Compliance requires market value to reach at least $35 million for 10 consecutive business days during the grace period.
• Failure to regain compliance by the deadline could trigger a delisting notice, with an option to appeal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-080741), on July 06, 2026, and is solely responsible for the information contained therein.